Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
      • Hemcast
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis

    • Coronavirus disease (COVID-19)

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Scientific Resources
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

The Value Of Medicines for Type 2 Diabetes

The Value Of Medicines for Type 2 Diabetes
OUR PURPOSE/ The Value Of Medicines for Type 2 Diabetes
October 1, 2014

Type 2 Diabetes (T2D) is one of the most common, costly, and preventable chronic health problems, comprising 90% of all diabetes cases.1 Medicines to treat T2D, including insluin therapy and other medications, have dramatically improved both the length and quality of life for people with T2D, and the development of new treatments is becoming increasingly important as more and more people are diagnosed with the disease.

Globally, there are 371 million people living with diabetes, and by 2030 this number is expected to grow to 552 million.2,3

T2D is a condition characterized by high levels of glucose (sugar) in the blood. Being overweight or obese, maintaining a poor diet, and a sedentary lifestyle are major contributors to the development of T2D. People with T2D have an increased risk of developing other serious health problems, including blindness, heart attack, kidney failure and amputation. For example, in the United States, 2% of people with diabetes become blind and 10% develop severe visual impairment.4,5 In the United Kingdom, 120 diabetic foot amputations occur weekly, and only 50% of patients survive two years after surgery.6

While T2D is still a lifelong, chronic illness that can be debilitating, and sometimes fatal, before the discovery of insulin in 1921, a diagnosis of diabetes almost always meant a person would die. Prior to being established as an insulin deficiency disease, children with the disease rarely lived a year after diagnosis, while 5% of adults died within two years, and less than 20% lived more than ten.7

vom_type2_diabetes_infographic1_620px.png

Sources: History of Insulin. International Islet Isolation and Transplantation Workshop from the Network of Islet Centers in Europe (NICE). // History of Insulin. Diabetes.co.uk, the global diabetes community.

Patient Impact

Left untreated, diabetes can cause severe morbidity and death. But thanks to available medicines, advances in health management techniques, and disease education and awareness, most diagnosed with T2D can go on to live long, healthy lives.

Below are two stories outlining the journey a patient, her mother, and their physician experienced using medicines to treat Type 2 diabetes.

Patient’s Story

My grandmother had Type 2 diabetes, and so did my mom. I did not want to end up like they did and was willing to do anything. When I went to visit Dr. Zemel, he was very concerned about my health because I have other diseases, too. Dr. Zemel suggested I meet with a nutritionist regarding adjustments to my diet and exercise, and prescribed one of the newer Type 2 diabetes drugs.

I immediately began seeing results due to my lifestyle changes and the medication. My daughter and I are doing more things together, like visiting college campuses now that she’s 18. Two years ago my health would not have allowed me to see as many campuses, or as much of them.

I am grateful to my doctor for recognizing my health risk and putting me on a program. Would I have been able to have done this with just diet and exercise alone? I don’t know. This combination has certainly worked for me.
-S.T., Colorado

Provider’s Story

Success in this mother/daughter pair delivers a story that typifies the value of medicine. They both benefitted in ways that are on the current mindset of our society. The two shared a starting weight of 185 pounds and had typical co-morbidities from their obesity. This caused the need for multiple medications to address diabetes, hypertension, and hyperlipidemia. These are all known risk factors for heart disease. Our care plan was to address their problems with a combination of behavioral modification and a newer class of diabetes medication that was more appropriate in its glucose-lowering effect.

The patients’ success was evident when they reached the weight of 160 pounds, reverted their diabetes back to a normal metabolic pattern, and continued to live and function well together while encouraging each other with their success. Medications for other co-morbid conditions were able to be discontinued as well.
- Dr. Zemel, Colorado

Societal Health Impact

While lifestyle changes such as dietary modifications, increased exercise, and reduced stress are an important part of managing T2D, and likely to be the first recommendations from health care providers, for many patients these methods alone are insufficient in managing the disease. For many with T2D medication is a necessary counterpart to lifestlye changes and other non-clinical efforts to control diabetes and its complications.

While several medicines exists for treating T2D, it is a progressive disease, meaning medicines initially effective at controlling a patient’s blood sugar levels may lose efficacy years later, despite using higher doses.10 When this occurs patients must progress to other medicines to maintain control of the disease. This highlights the undeniable value of, and medical need for, new medicines with improved durability, safety profiles and impact on non-insulin parameters, such as weight and blood pressure.

Several classes of medicines being studied, or recently approved for marketing, address this medical need. For example, some new medicines are focused on the role kidneys play in controlling blood sugar levels, and by increasing urinary excretion of glucose are able to lower blood sugar independent of insulin.11 Other new medicines are able to increase glucose-dependent pancreatic insulin production, helping reduce incidence of hypoglycemia compared to older medicines.12 Additionally, insulin is also seeing innovative advances as companies focus on inhalable delivery systems, and formulations which more closely resemble the insulin activity of healthy patients.

Newer medicines for T2D are demonstrating easier dosing, fewer side effects, and greater efficacy.

These new treatment options and the continued innovation of diabetes medicines offer new hope for society, patients, and caregivers; along with advancements in science for governments, academia, and industry alike. As the burden of type 2 diabetes increases globally, so too should the armamentarium to combat it.

Economic Impact

Global healthcare expenditures on diabetes were estimated to be at approximately $465 billion in 2011 and are estimated to grow to $595 billion in 2030.13 The increasing cost of diabetes is largely attributable to the immense growth in the prevalence of the disease. In the U.S., from 1995 to 2010, there was at least a 100% increase in the prevalence of diagnosed diabetes cases in 18 states and forty-two states saw an increase of at least 50%.14

As more and more people are diagnosed with diabetes, costs associated with treating both the disease and its complications become more and more burdensome. Additionally, the indirect costs of T2D includes things like absenteeism, reduced productivity, inability to work, and early mortality. In 2012 in the U.S., indirect costs of diabetes were estimated to be $68.6 billion.15

vom_type2_diabetes_infographic2_620px.png

Source: American Diabetes Association. The Cost of Diabetes. http://www.diabetes.org/advocate/resources/cost-of-diabetes.html

Yet, as prevalence grows and the cost of diabetes rises, medicines to treat diabetes continue to represent a small share of expenditures, despite the introduction of many new classes of medication and their central role in controlling and combating the disease.

Compared with other costs associated with the treatment and management of diabetes, diabetes medicines are a relative drop in the bucket. However, the true value of T2D medicines is perhaps best supported by the economic case for improved adherence.

Despite having access to medicines, many diabetes patients are nonadherent to treatment, either missing doses or not complying with treatment plans altogether. It is estimated that as many as 60% of T2D patients are nonadherent.16 Patients who are nonadherent are far more likely to require hospitalization and to incur significantly higher healthcare costs. Because of this, many economists and health professionals alike advocate the increased utilization of, or adherence to, diabetes medicines as a way to not only improve health, but also to lower health care costs.17

A study conducted in 2012 found that improved drug adherence to diabetes medicines was associated with 13 percent lower odds of subsequent hospitalizations or emergency department visits. Based on these and other effects, the study authors projected that improved adherence to diabetes medicine could avert 699,000 emergency department visits and 341,000 hospitalizations annually, for a saving of $4.7 billion.1

vom_type2_diabetes_infographic3_620px.png

Adapted from: M. Sokol et al., “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost,” Journal of Medical Care, 2005.
Notes: Adherence is the extent to which patients take medicines as prescribed, in terms of dose and duration. Return on Investment estimates reflect spending attributable to the condition listed.

Endnotes

  1. Chronic Disease and Health Promotion. Centers for Disease Control and Prevention.Accessed June 24, 2013 from http://www.cdc.gov/chronicdisease/overview/index.htm
  2. International Diabetes Federation. Healthcare Expenditures. IDF Diabetes Atlas, Fifth Edition. IDF DIABETES ATLAS UPDATE 2012. Retrieved June 24, 2013 from http://www.idf.org/diabetesat-las/5e/Update2012
  3. International Diabetes Federation. Healthcare Expenditures. IDF Diabetes Atlas, Fifth Edition. IDF DIABETES ATLAS UPDATE 2012. Retrieved June 24, 2013 from http://www.idf.org/diabetesat-las/5e/the-global-burden
  4. World Health Organization. Diabetes mellitus. http://www.who.int/mediacentre/factsheets/fs138/en/
  5. Fronstin, Michael. Stemming the costs of diabetes. Kantar Health. November 2012
  6. Diabetes UK. Putting Feet First. February 2013. http://www.diabetes.org.uk/Documents/Reports/putting-feet-first-foot-attack-report022013.pdf
  7. Berger, Melvin. “Frederick Grant Banting.” Famous Men of Modern Biology. New York: Thomas Y. Crowell Company, 1968.
  8. American Diabetes Association. The Cost of Diabetes. http://www.diabetes.org/advocate/resources/cost-of-diabetes.html
  9. M. Sokol et al., “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost,” Journal of Medical Care, 2005.
  10. Diabetes Myths. American Diabetes Association http://www.diabetes.org/diabetes-basics/diabetes-myths/
  11. Ghosh, R. et al. SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus. http://www.iqanda-cme.com/assets/pdf/Ghosh.pdf
  12. Rotenstien, Lisa S., et.al. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We? Clinical Diabetes. Vol. 30, No.2
  13. International Diabetes Federation. Healthcare Expenditures. IDF Diabetes Atlas, Fifth Edition. Retrieved June 6, 2013 from http://www.idf.org/diabetesatlas/5e/healthcare-expenditures
  14. Morbidity and Mortality Weekly Report (MMWR), Centers for Disease Control and Prevention http://www.cdc.gov/media/mmwrnews/2012/1115.html#C3
  15. American Diabetes Association. The Cost of Diabetes 2012. http://www.diabetes.org/advocate/resources/cost-of-diabetes.html
  16. Wild, H. The Economic Rationale for Adherence in the Treatment of Type 2 Diabetes Mellitus. American Journal of Managed Care. http://www.ajmc.com/publications/supplement/2012/A405_12Apr_Diabetes/The-Economic-Rationale-for-Adherence-in-the-Treatment-of-Type-2-Diabetes-Mellitus/
  17. http://www.ajmc.com/publications/supplement/2012/a405_12apr_diabetes/the-economic-rationale-for-adherence-in-the-treatment-of-type-2-diabetes-mellitus/1
  18. Ashish K. Jha et al. Greater Adherence to Diabetes Drugs is linked to Less Hospital Use and Could Save Nearly $5 Billion Annually. Health Affairs, 31, No.8 (2012): 1836-1846.

Issued by Global Policy and International Public Affairs

 pfizer-rxpathways-logo

Download the Value of Medicines for Type 2 Diabetes article in PDF format.

KEY TAKEAWAYS

Before insulin discovery and the availability of insulin therapy, diabetic children rarely lived a year after diagnosis, 5% of adults died within two years, and less than 20% lived more than ten.7


The cost of diabetes is skyrocketing due to increasing prevalence of the disease, however, medicines to treat diabetes represent a small share of expenditures on diabetes care, despite their central role in controlling and combating the disease.8


$1 more spent on diabetes medicines equals $7.10 less spent on other services to treat diabetes.9

Related Hot Topics
Media Name: vom_cholesterol300x170.jpg
Value of Cholesterol Lowering Medications
vom_stroke_300x170.jpg
Value of Medicines Stroke and Atrial Fibrillation
Smoking Cessation
Value of Medicine for Smoking Cessation
Tags
Value of Medicines Metabolic
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.